investors can Contact the law firm for free to learn more about recovering their losses

?LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) — The law firm of Portnoy advises Accelerate Diagnostics, Inc. AXDX Investors that the law firm has opened an investigation on behalf of investors who lost money on their Accelerate Diagnostics stock. Accelerate Diagnostics investors are encouraged to do so Contact the company to discuss their legal rights.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: [email protected]to discuss your legal rights, or click here to join the case about www.portnoylaw.com. Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

On October 21, 2022, after the market close, Accelerate Diagnostics filed an update report with the SEC on Form 8-K, disclosing that the Company, pursuant to discussions with the U.S. Food and Drug Administration (“FDA”) among other things: “(i) discontinu[e] the US marketing and distribution of [its Accelerate Arc system and related BC Kit (collectively, the “Accelerate Arc Products”)] for processing positive blood cultures and subsequent identification by mass spectrometry for diagnostic purposes; (ii) remove[e] and/or any US promotional information within the Company’s control (e.g., website, labeling, social media, sales representative information, or other promotional material) relating to the diagnostic use of the Accelerate Arc products as Class I devices or as positive intended devices correct devices for processing blood cultures for subsequent identification of microorganisms by mass spectrometry; and (iii) revise[e]/remove[e] the Company’s registration and listing of Accelerate Arc products as Class I devices.”

So far, “[t]The company had listed the Accelerate Arc products as a Class I device that was exempt from 510(k) clearance requirements[,]”, but “the FDA has clarified that the…